Introduction

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 1, 2007, Pages

  Rolston, Kenneth V I ^a   Segreti, John ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; METICILLIN; MINOCYCLINE; ORITAVANCIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; GRAM POSITIVE BACTERIUM; HUMAN; PRIORITY JOURNAL;

EID: 34648831527     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.007     Document Type: Editorial

References (13)

1. Bad Bugs, No Drugs. Infectious Diseases Society of America, July 2004. Available at: http://www.idsociety.org/pa/IDSA_ Paper4_ final_ web.pdf. Accessed August 20, 2007.
2. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., Bartlett J.G., and Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
3. Moellering Jr. R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 42 suppl 1 (2006) S3-S4
4. Kapadia M., Coyle E., Prince R., and Rolston K. Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at the 45th Annual Meeting of Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) (2005), Ameican Society for Microbiology, Washington DC 168 Abstract E-807.
5. Safdar A., and Rolston K.V. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 106 (2006) 1815-1820
6. Fowler Jr. V.G., Sakoulas G., McIntyre L.M., et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus: infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 190 (2004) 1140-1149
7. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 44 (2007) 1543-1548
8. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 (2004) 994-1000
9. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein BI, and and the Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
10. Zyvox. [prescribing information] (2007), Pfizer Inc, New York, NY
11. Raad I., Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 40 (2005) 374-380
12. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
13. Bishop E., Melvani S., Howden B.P., Charles P.G., and Grayson M.L. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50 (2006) 1599-1602